15.56
price up icon0.81%   0.15
after-market Handel nachbörslich: 15.32 -0.24 -1.54%
loading
Schlusskurs vom Vortag:
$15.41
Offen:
$15.42
24-Stunden-Volumen:
806.87K
Relative Volume:
1.42
Marktkapitalisierung:
$631.98M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.05M
KGV:
-3.0331
EPS:
-5.13
Netto-Cashflow:
$-146.15M
1W Leistung:
+7.21%
1M Leistung:
-2.30%
6M Leistung:
+11.84%
1J Leistung:
-73.82%
1-Tages-Spanne:
Value
$15.03
$15.76
1-Wochen-Bereich:
Value
$13.60
$15.76
52-Wochen-Spanne:
Value
$9.12
$72.37

Keros Therapeutics Inc Stock (KROS) Company Profile

Name
Firmenname
Keros Therapeutics Inc
Name
Telefon
617-314-6297
Name
Adresse
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Name
Mitarbeiter
148
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
KROS's Discussions on Twitter

Vergleichen Sie KROS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
KROS
Keros Therapeutics Inc
15.56 469.48M 0 -168.05M -146.15M -5.13
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
426.43 109.29B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.90 62.13B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
584.65 61.40B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
813.45 51.39B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.96 34.68B 4.56B -176.77M 225.30M -1.7177

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-10-20 Eingeleitet Wells Fargo Overweight
2025-06-10 Herabstufung BofA Securities Buy → Neutral
2025-01-21 Herabstufung Cantor Fitzgerald Overweight → Neutral
2025-01-17 Herabstufung Wedbush Outperform → Neutral
2024-12-16 Herabstufung Guggenheim Buy → Neutral
2024-12-16 Bestätigt Oppenheimer Outperform
2024-12-13 Bestätigt H.C. Wainwright Buy
2024-12-12 Herabstufung BTIG Research Buy → Neutral
2024-12-12 Herabstufung TD Cowen Buy → Hold
2024-12-12 Herabstufung William Blair Outperform → Mkt Perform
2024-11-05 Eingeleitet Jefferies Buy
2024-10-24 Eingeleitet Cantor Fitzgerald Overweight
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-09-23 Eingeleitet Guggenheim Buy
2024-06-25 Eingeleitet Oppenheimer Outperform
2024-02-21 Eingeleitet William Blair Outperform
2023-12-08 Eingeleitet Wells Fargo Overweight
2023-07-31 Eingeleitet Wedbush Outperform
2023-07-26 Eingeleitet BofA Securities Buy
2023-02-14 Eingeleitet Cowen Outperform
2022-10-18 Eingeleitet Truist Buy
2022-07-26 Eingeleitet BTIG Research Buy
2020-12-08 Bestätigt H.C. Wainwright Buy
2020-05-04 Eingeleitet H.C. Wainwright Buy
2020-05-04 Eingeleitet Jefferies Buy
2020-05-04 Eingeleitet Piper Sandler Overweight
2020-05-04 Eingeleitet SVB Leerink Outperform
Alle ansehen

Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten

pulisher
Oct 21, 2025

Technical Reactions to KROS Trends in Macro Strategies - news.stocktradersdaily.com

Oct 21, 2025
pulisher
Oct 21, 2025

Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last? - Yahoo Finance

Oct 21, 2025
pulisher
Oct 21, 2025

Can Keros Therapeutics Inc. recover in the next quarterMarket Risk Summary & Community Consensus Picks - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Using flow based indicators on Keros Therapeutics Inc.July 2025 Update & AI Powered Market Entry Strategies - newser.com

Oct 21, 2025
pulisher
Oct 20, 2025

Keros Therapeutics Inc. stock trendline breakdownWeekly Investment Recap & AI Optimized Trading Strategy Guides - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Keros Therapeutics (NASDAQ:KROS) Trading Up 10.8%Still a Buy? - MarketBeat

Oct 20, 2025
pulisher
Oct 20, 2025

Why Keros Therapeutics Inc. stock remains undervaluedLong Setup & Accurate Entry/Exit Alerts - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Published on: 2025-10-20 18:43:57 - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Reversal indicators forming on Keros Therapeutics Inc. stockPortfolio Risk Report & Weekly High Potential Stock Alerts - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

What hedge fund activity signals for Keros Therapeutics Inc. stockTrade Ideas & Long-Term Investment Growth Plans - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Can trapped investors hope for a rebound in Keros Therapeutics Inc.July 2025 Catalysts & Reliable Momentum Entry Alerts - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Keros Therapeutics Inc. stock daily chart insightsMarket Performance Recap & Capital Efficient Trade Techniques - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Keros Therapeutics (KROS) Launches $194.4 Million Stock Buyback - GuruFocus

Oct 20, 2025
pulisher
Oct 20, 2025

Wells Fargo & Company Initiates Coverage on Keros Therapeutics (NASDAQ:KROS) - MarketBeat

Oct 20, 2025
pulisher
Oct 20, 2025

Will breakout in Keros Therapeutics Inc. lead to full recovery2025 Fundamental Recap & Reliable Price Breakout Alerts - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Keros Therapeutics (KROS) Initiates Tender Offer for Share Buyback - GuruFocus

Oct 20, 2025
pulisher
Oct 20, 2025

Keros Therapeutics Launches Tender Offer for Up to $194.4 Million of Shares - MarketScreener

Oct 20, 2025
pulisher
Oct 20, 2025

Keros Therapeutics (KROS) Initiates $194.4M Stock Buyback Progra - GuruFocus

Oct 20, 2025
pulisher
Oct 20, 2025

Keros Therapeutics launches $194.4 million share repurchase tender offer - Investing.com

Oct 20, 2025
pulisher
Oct 20, 2025

Keros (KROS) launches fixed-price cash tender offer for shares - Stock Titan

Oct 20, 2025
pulisher
Oct 20, 2025

$194.4M Tender Offer — Keros Therapeutics to Repurchase at $17.75; Part of $375M Program. Expires Nov. 18, 2025 - Stock Titan

Oct 20, 2025
pulisher
Oct 19, 2025

Historical volatility pattern of Keros Therapeutics Inc. visualized2025 Valuation Update & High Accuracy Trade Alerts - newser.com

Oct 19, 2025
pulisher
Oct 18, 2025

Keros Therapeutics (NASDAQ:KROS) Major Shareholder Sells $84,975,125.25 in Stock - MarketBeat

Oct 18, 2025
pulisher
Oct 18, 2025

Chipmakers Recap: Is Keros Therapeutics Inc. stock supported by strong fundamentalsWeekly Profit Report & Real-Time Volume Analysis - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

What momentum indicators show for Keros Therapeutics Inc. stockQuarterly Profit Summary & Daily Entry Point Alerts - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Is Keros Therapeutics Inc. stock supported by strong fundamentalsWeekly Trade Review & Accurate Buy Signal Notifications - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Is Keros Therapeutics Inc. stock a buy on dipsWatch List & Advanced Swing Trade Entry Alerts - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 17, 2025

Earnings visualization tools for Keros Therapeutics Inc.Trade Ideas & Daily Stock Momentum Reports - newser.com

Oct 17, 2025
pulisher
Oct 17, 2025

Sarcopenia Market Insights Highlight Expanding Outlook Till - openPR.com

Oct 17, 2025
pulisher
Oct 17, 2025

Sarcopenia Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross - Barchart.com

Oct 17, 2025
pulisher
Oct 17, 2025

Pontifax funds sell Keros Therapeutics (KROS) shares for $84.97m By Investing.com - Investing.com Australia

Oct 17, 2025
pulisher
Oct 17, 2025

Pontifax funds sell Keros Therapeutics (KROS) shares for $84.97m - Investing.com India

Oct 17, 2025
pulisher
Oct 17, 2025

KROS insiders file Form 4; Pontifax funds report stock sales - Stock Titan

Oct 17, 2025
pulisher
Oct 17, 2025

How to recover losses in Keros Therapeutics Inc. stock2025 Price Action Summary & Verified Momentum Stock Ideas - newser.com

Oct 17, 2025
pulisher
Oct 17, 2025

Is Keros Therapeutics Inc. stock poised for growthSwing Trade & Community Consensus Picks - newser.com

Oct 17, 2025
pulisher
Oct 17, 2025

Keros Therapeutics, Inc. (KROS) Stock Analysis: Unpacking a 67% Potential Upside Amidst Robust Revenue Growth - DirectorsTalk Interviews

Oct 17, 2025
pulisher
Oct 17, 2025

Forecasting Keros Therapeutics Inc. price range with options dataWall Street Watch & Long-Term Capital Growth Ideas - newser.com

Oct 17, 2025
pulisher
Oct 16, 2025

Keros Therapeutics (NASDAQ:KROS) Major Shareholder Adar1 Capital Management, Llc Sells 5,389,264 Shares - MarketBeat

Oct 16, 2025
pulisher
Oct 16, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Looks Inexpensive But Perhaps Not Attractive Enough - 富途牛牛

Oct 16, 2025
pulisher
Oct 16, 2025

Keros Therapeutics Unveils Major Capital Return Initiative Amid Leadership Reshuffle - AD HOC NEWS

Oct 16, 2025
pulisher
Oct 15, 2025

Keros Therapeutics Sparks Market Interest With Nasdaq Futures - Kalkine Media

Oct 15, 2025
pulisher
Oct 15, 2025

Keros Therapeutics Plans Major Buyback And Tender Offer - Finimize

Oct 15, 2025
pulisher
Oct 15, 2025

Adar1 partners sells Keros Therapeutics (KROS) shares worth $95.6m By Investing.com - Investing.com Nigeria

Oct 15, 2025
pulisher
Oct 15, 2025

Adar1 partners sells Keros Therapeutics (KROS) shares worth $95.6m - Investing.com

Oct 15, 2025
pulisher
Oct 15, 2025

Keros Therapeutics (NASDAQ:KROS) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat

Oct 15, 2025
pulisher
Oct 15, 2025

Keros Therapeutics Announces Plan for Return of $375 Million In Excess Capital - citybiz

Oct 15, 2025

Finanzdaten der Keros Therapeutics Inc-Aktie (KROS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$36.84
price down icon 1.75%
$88.04
price up icon 0.88%
$29.91
price down icon 0.65%
$106.22
price down icon 0.54%
$160.40
price down icon 3.15%
biotechnology ONC
$313.96
price down icon 0.62%
Kapitalisierung:     |  Volumen (24h):